A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Trial details
- Registry ID
- NCT06695845
- Phase
- Phase 2
The FDA approved Zanidatamab (JZP598) on 20 Nov 2024.
Drug identity checked against registry records
Also recorded as JZP598; ZIIHERA®; ZW25
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2024-11-20Day | Zanidatamab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761416", "applicant_as_listed_by_fda": "JAZZ PHARMS", "brand_names": ["ZIIHERA"], "active_ingredients": ["ZANIDATAMAB-HRII"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20241120", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |